Panacea Index Logo

Command Palette

Search for a command to run...

Analysis of the SYSDIET Healthy Nordic Diet randomized trial based on metabolic profiling reveal beneficial effects on glucose metabolism and blood lipids.

Clinical nutrition (Edinburgh, Scotland)
February 1, 2022
Gözde Gürdeniz et al. (19 authors)
Journal ArticleMulticenter StudyResearch Support, Non-U.S. Gov'tHuman Study
Study Details

Study Goal

The researchers aimed to assess the effects of a healthy Nordic diet (including low-fat dairy) on metabolic profiles and cardiometabolic markers compared to a control diet.

Results Summary

The study found that the healthy Nordic diet (including low-fat dairy) was distinguishable from the control diet via metabolic profiles, with associations to improved HDL, triglycerides, and glucose metabolism. Dairy-specific effects were not isolated but contributed to the overall dietary pattern.

Population

200 participants with metabolic syndrome across six centers.

Effective Dosage

Not specified (dietary advice included low-fat dairy as part of the Nordic diet).

Duration

18-24 weeks.

Interactions

None mentioned.

Extracted Claims (10)
InterventionDirectionEndpointPopulationDosageImpactClaim #
healthy Nordic diet (HND)
neutral
plasma metabolic profile
participants with metabolic syndrome
AUC of 0.96 ± 0.03
distinguished from Control diet (CD)
#1
healthy Nordic diet (HND)
neutral
urine metabolic profile
participants with metabolic syndrome
AUC of 0.93 ± 0.02
distinguished from Control diet (CD)
#2
healthy Nordic diet (HND)
neutral
markers of fish, whole grain and polyunsaturated lipids
participants with metabolic syndrome
-
characterized by
#3
Control diet (CD)
neutral
lipids containing palmitoleic acid
participants with metabolic syndrome
-
reflected by
#4
healthy Nordic diet (HND)
increase
HDL
participants with metabolic syndrome
β = 0.05; 95% CI: 0.02, 0.08; P = 0.001
associated with
#5
healthy Nordic diet (HND)
decrease
triglycerides
participants with metabolic syndrome
β = -0.06; 95% CI: -0.09, -0.03; P < 0.001
associated with
#6
healthy Nordic diet (HND)
increase
2 h Glucose
participants with metabolic syndrome
β = 0.1; 95% CI: 0.05, 0.15; P < 0.001
related with
#7
healthy Nordic diet (HND)
increase
LDL
participants with metabolic syndrome
β = 0.06; 95% CI: 0.01, 0.1; P = 0.02
related with
#8
healthy Nordic diet (HND)
increase
triglycerides
participants with metabolic syndrome
β = 0.11; 95% CI: 0.06, 0.15; P < 0.001
related with
#9
healthy Nordic diet (HND)
neutral
LDL cholesterol
participants with metabolic syndrome
-
related with
#10
Abstract

BACKGROUND & AIMS: Intake assessment in multicenter trials is challenging, yet important for accurate outcome evaluation. The present study aimed to characterize a multicenter randomized controlled trial with a healthy Nordic diet (HND) compared to a Control diet (CD) by plasma and urine metabolic profiles and to associate them with cardiometabolic markers. METHODS: During 18-24 weeks of intervention, 200 participants with metabolic syndrome were advised at six centres to eat either HND (e.g. whole-grain products, berries, rapeseed oil, fish and low-fat dairy) or CD while being weight stable. Of these 166/159 completers delivered blood/urine samples. Metabolic profiles of fasting plasma and 24 h pooled urine were analysed to identify characteristic diet-related patterns. Principal components analysis (PCA) scores (i.e. PC1 and PC2 scores) were used to test their combined effect on blood glucose response (primary endpoint), serum lipoproteins, triglycerides, and inflammatory markers. RESULTS: The profiles distinguished HND and CD with AUC of 0.96 ± 0.03 and 0.93 ± 0.02 for plasma and urine, respectively, with limited heterogeneity between centers, reflecting markers of key foods. Markers of fish, whole grain and polyunsaturated lipids characterized HND, while CD was reflected by lipids containing palmitoleic acid. The PC1 scores of plasma metabolites characterizing the intervention is associated with HDL (β = 0.05; 95% CI: 0.02, 0.08; P = 0.001) and triglycerides (β = -0.06; 95% CI: -0.09, -0.03; P < 0.001). PC2 scores were related with glucose metabolism (2 h Glucose, β = 0.1; 95% CI: 0.05, 0.15; P < 0.001), LDL (β = 0.06; 95% CI: 0.01, 0.1; P = 0.02) and triglycerides (β = 0.11; 95% CI: 0.06, 0.15; P < 0.001). For urine, the scores were related with LDL cholesterol. CONCLUSIONS: Plasma and urine metabolite profiles from SYSDIET reflected good compliance with dietary recommendations across the region. The scores of metabolites characterizing the diets associated with outcomes related with cardio-metabolic risk. Our analysis therefore offers a novel way to approach a per protocol analysis with a balanced compliance assessment in larger multicentre dietary trials. The study was registered at clinicaltrials.gov with NCT00992641.

Medical Subject Headings (MeSH)
Area Under CurveBiomarkersBlood GlucoseCardiometabolic Risk FactorsDiet, HealthyEatingFastingFemaleHumansInflammation MediatorsLipidsLipoproteinsMaleMetabolic SyndromeMetabolomicsMiddle AgedNutrition AssessmentOverweightPrincipal Component AnalysisRandomized Controlled Trials as TopicScandinavian and Nordic CountriesTriglycerides
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations14
Citations/Year4.7
Relative Citation Ratio1.72
NIH Percentile69.8%
Research Impact Scores
APT Score0.75
Weight Score2.81
Normalized Score0.67
Related Supplements